← All organizations
Highest phase reached
Phase 3
First clinical trial
Jan 1, 2004Last known activity
Jul 25, 2025
Timeline
2000s
- Jan 1, 2004
Center for International Blood and Marrow Transplant Research— Founded
Drugs by trial phase (55 distinct, 45 trials)
Phase 3 (35 own, 0 via acquisition)
Phase 2 (19 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Anemia, Aplastic
- Anemia, Sickle Cell
- Communicable Diseases
- Graft vs Host Disease
- Hodgkin Disease
- Immune System Diseases
- Infections
- Leukemia
- Leukemia, Biphenotypic, Acute
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Mycoses
- Myelodysplastic-Myeloproliferative Diseases
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm, Residual
- Neoplasms, Plasma Cell
- Plasmablastic Lymphoma
- Pneumonia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Syndrome
Recent trials (47)
- NCT06859424Lead sponsorPhase 2Jul 25, 2025
- NCT06001385Lead sponsorPhase 2Nov 1, 2023
- NCT05589896CollaboratorPhase 1/Phase 2Mar 31, 2023
- NCT05589896Study chairPhase 1/Phase 2Mar 31, 2023
- NCT05600426CollaboratorPhase 3Dec 31, 2022
- NCT05068401Lead sponsorPhase 1Mar 31, 2022
- NCT05170828CollaboratorPhase 1Mar 31, 2022
- NCT05170828Study chairPhase 1Mar 31, 2022
- NCT04934670Study directorPhase 3Dec 1, 2021
- NCT04904588Lead sponsorPhase 2Sep 30, 2021
- NCT03971799Lead sponsorPhase 1/Phase 2Oct 31, 2019
- NCT03959241Study directorPhase 3Jun 30, 2019
- NCT03263559Study directorPhase 2Oct 3, 2017
- NCT02918292Study directorPhase 2Sep 1, 2017
- NCT03434808Lead sponsorN/AJan 13, 2017
Details
- Founded
- Milwaukee, WI, US Jan 1, 2004
- Last known activity
- Jul 25, 2025